Episode 72: Trying to Outpace Rare Disease

The top five episodes of our podcast in the year 2024, highlighted.

LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.

Panna Sharma, CEO of Lantern Pharma, discusses garage biotech, what he’s learned from the culture, and how it might help transform certain areas of pharma, including innovation and pricing.

Peter Ax, founder & CEO of UpScriptHealth, discusses the impact of tariffs on the pharmaceutical industry and how digital health platforms could potentially help offset them.

Jim and Cindy DiBiasi, co-founders of 3D Communications, talk about how to prepare for virtual high-level meetings, such as important regulatory presentations and keynote addresses, in the wake of COVID-19.

Tim Walbert, CEO of Horizon Therapeutics, shares his unique perspective on managing a company through COVID-19, in light of the fact that he himself is immunocompromised.